CEO Willis Lee Buys $18K of Emmaus Stock Across Six Trades
EMMA has more than doubled off its 52-week low of $0.008 on light trading volume (0.3× avg).
Summary
CEO Willis Lee bought $18,126 of Emmaus stock in six open-market trades over 15 months, lifting his total holdings to 690,167 shares.
Key Events · Ownership and Investor Activity · EMMA
-
CEO Buys 530,767 Shares
Willis C. Lee acquired 530,767 shares for $18,126.02 across six open-market purchases between 2025-05-30 and 2026-08-31, at prices ranging from $0.01 to $0.06.
-
Post-Transaction Holdings
Lee now holds 690,167 shares total — 395,124 directly and 295,043 indirectly via Fidelity Roth and Traditional IRAs.
-
Going-Concern Backdrop
The purchases follow Emmaus's August 14 10-Q, which disclosed a going-concern warning and a $60.1 million working capital deficit.
-
Recent Buying Cluster
Four of the six purchases occurred in the last week of August 2026, totaling 290,767 shares at $0.04–$0.06 per share.
Analysis · EMMA · Life Sciences
CEO Willis C. Lee purchased 530,767 shares for $18,126 across six open-market transactions between May 2025 and August 2026, at prices from $0.01 to $0.06. The purchases come as Emmaus faces a going-concern warning and a $60.1 million working capital deficit disclosed in its August 14 10-Q. While the dollar amount is modest, the CEO's repeated buying at depressed prices is a real-money vote of confidence from the person closest to operations.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1753 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EMMA was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.01 to $0.09. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.